ALMS - CIK 0001847367
ALUMIS INC. trades as ALMS and has a market capitalization of $2.74 B, making it the #1885 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $24.05M and net income of -$243.32M. This page tracks ALUMIS INC. through 218 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Annual report to shareholders | ARS | 2026-05-18 |
| Proxy materials | DEFA14A | 2026-05-18 |
| Proxy statement | DEF 14A | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| SCHEDULE 13G | - | 2026-04-07 |
| Insider trade | 4 | 2026-04-03 |
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements | Alumis Inc.
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Alumis Inc.
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | Alumis Inc.
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting | Alumis Inc.
Alumis to Present at the Leerink Partners Global Healthcare Conference | Alumis Inc.
The largest companies sharing ALUMIS INC.'s SEC industry classification (pharmaceutical preparations).
ALUMIS INC. (ALMS) has a market capitalization of $2.74 B as of 2026-05-29, ranking #1885 among US-listed companies.
ALUMIS INC. reported revenue of $24.05M for fiscal year 2025.
In its latest fiscal year ALUMIS INC. reported a net loss of $243.32M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.